An investor asked a question on the investor interaction platform: May I ask the Secretary, many innovative drugs that have recently gone to sea have been rejected by FDA because the experimental data structure is not comprehensive. I would like to ask, in the 627 phase III experiment and head-to-head experiment conducted by our company in the United States, the distribution of patients in the experimental data is mainly American patients? Or something else? Can you explain it! Thank you very much!
Yifan Pharmaceutical Co.Ltd(002019) (002019. SZ) said on the investor interaction platform on December 30 that the second international phase III clinical trial scheme (scheme 05) of the company’s subsidiary product f-627 under research was carried out under the condition of obtaining the spa (special scheme evaluation) of the US FDA.
(Daily Economic News)
